Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned favorably in the biopharmaceutical market due to its focus on developing therapies targeting clinically validated kinase mutations in cancer, exemplified by candidates like NVL-520 and NVL-655, which show promising efficacy and tolerability in large safety populations. The company anticipates a substantial market opportunity, particularly in the pre-treated ROS1 market, projecting strong uptake once the potential approval of zidesamtinib occurs in 2026, bolstered by positive feedback from key opinion leaders regarding evolving treatment paradigms in ALK-positive non-small cell lung cancer. Additionally, refined total addressable market (TAM) estimates suggest that the potential revenue from first-line (1L) and second-line (2L) treatments could range from $6.4 billion to $7.6 billion and $1.3 billion to $2.0 billion, respectively, indicating significant financial growth potential as the company advances its pipeline.

Bears say

Nuvalent Inc faces significant risks that could negatively impact its stock value, primarily stemming from potential underperformance of its key pipeline candidates, NVL-520 and NVL-655, which could result in revised market penetration estimates and elongated timelines for approval. Additionally, the emergence of superior competitor products and challenges in securing favorable reimbursement for its therapies pose substantial regulatory and commercial risks. Furthermore, ongoing data about adverse events (AEs) suggests a higher prevalence than anticipated, which could further complicate the company's market positioning and investor confidence.

Nuvalent (NUVL) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 11 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.